-
1
-
-
79951844263
-
Clinical course and prediction of survival in idiopathic pulmonary fibrosis
-
Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183: 431-440.
-
(2011)
Am J Respir Crit Care Med
, vol.183
, pp. 431-440
-
-
Ley, B.1
Collard, H.R.2
King, T.E.3
-
2
-
-
79952717349
-
An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management
-
Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
-
(2011)
Am J Respir Crit Care Med
, vol.183
, pp. 788-824
-
-
Raghu, G.1
Collard, H.R.2
Egan, J.J.3
-
3
-
-
84861911665
-
An earlier and more confident diagnosis of idiopathic pulmonary fibrosis
-
du Bois RM. An earlier and more confident diagnosis of idiopathic pulmonary fibrosis. Eur Respir Rev 2012; 21: 141-146.
-
(2012)
Eur Respir Rev
, vol.21
, pp. 141-146
-
-
Du Bois, R.M.1
-
4
-
-
33744916992
-
Classification and natural history of the idiopathic interstitial pneumonias
-
Kim DS, Collard HR, King TE Jr. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006; 3: 285-292.
-
(2006)
Proc Am Thorac Soc
, vol.3
, pp. 285-292
-
-
Kim, D.S.1
Collard, H.R.2
King, T.E.3
-
5
-
-
84930673517
-
Natural history of idiopathic pulmonary fibrosis
-
Kim HJ, Perlman D, Tomic R. Natural history of idiopathic pulmonary fibrosis. Respir Med 2015; 109: 661-670.
-
(2015)
Respir Med
, vol.109
, pp. 661-670
-
-
Kim, H.J.1
Perlman, D.2
Tomic, R.3
-
6
-
-
84455168726
-
Forced vital capacity in patients with idiopathic pulmonary fibrosis: Test properties and minimal clinically important difference
-
du Bois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011; 184: 1382-1389.
-
(2011)
Am J Respir Crit Care Med
, vol.184
, pp. 1382-1389
-
-
Du Bois, R.M.1
Weycker, D.2
Albera, C.3
-
7
-
-
84862826491
-
Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis
-
Richeldi L, Ryerson CJ, Lee JS, et al. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax 2012; 67: 407-411.
-
(2012)
Thorax
, vol.67
, pp. 407-411
-
-
Richeldi, L.1
Ryerson, C.J.2
Lee, J.S.3
-
8
-
-
84875208959
-
Forced vital capacity as a primary end point in idiopathic pulmonary fibrosis treatment trials: Making a silk purse from a sow's ear
-
Wells AU. Forced vital capacity as a primary end point in idiopathic pulmonary fibrosis treatment trials: making a silk purse from a sow's ear. Thorax 2013; 68: 309-310.
-
(2013)
Thorax
, vol.68
, pp. 309-310
-
-
Wells, A.U.1
-
9
-
-
84901817527
-
Staging of idiopathic pulmonary fibrosis: Past, present and future
-
Kolb M, Collard HR. Staging of idiopathic pulmonary fibrosis: past, present and future. Eur Respir Rev 2014; 23: 220-224.
-
(2014)
Eur Respir Rev
, vol.23
, pp. 220-224
-
-
Kolb, M.1
Collard, H.R.2
-
10
-
-
84861162888
-
A multidimensional index and staging system for idiopathic pulmonary fibrosis
-
Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012; 156: 684-691.
-
(2012)
Ann Intern Med
, vol.156
, pp. 684-691
-
-
Ley, B.1
Ryerson, C.J.2
Vittinghoff, E.3
-
11
-
-
84958040637
-
Idiopathic pulmonary fibrosis: Gender-Age-Physiology index stage for predicting future lung function decline
-
Salisbury ML, Xia M, Zhou Y, et al. Idiopathic pulmonary fibrosis: Gender-Age-Physiology index stage for predicting future lung function decline. Chest 2016; 149: 491-498.
-
(2016)
Chest
, vol.149
, pp. 491-498
-
-
Salisbury, M.L.1
Xia, M.2
Zhou, Y.3
-
12
-
-
84901759236
-
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis
-
King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083-2092.
-
(2014)
N Engl J Med
, vol.370
, pp. 2083-2092
-
-
King, T.E.1
Bradford, W.Z.2
Castro-Bernardini, S.3
-
13
-
-
79956341531
-
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials
-
Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760-1769.
-
(2011)
Lancet
, vol.377
, pp. 1760-1769
-
-
Noble, P.W.1
Albera, C.2
Bradford, W.Z.3
-
14
-
-
84937574973
-
Sensitivity analyses of the change in FVC in a phase 3 trial of pirfenidone for idiopathic pulmonary fibrosis
-
Lederer DJ, Bradford WZ, Fagan EA, et al. Sensitivity analyses of the change in FVC in a phase 3 trial of pirfenidone for idiopathic pulmonary fibrosis. Chest 2015; 148: 196-201.
-
(2015)
Chest
, vol.148
, pp. 196-201
-
-
Lederer, D.J.1
Bradford, W.Z.2
Fagan, E.A.3
-
15
-
-
0031912648
-
Validation of a new dyspnea measure: The UCSD Shortness of Breath Questionnaire
-
Eakin EG, Resnikoff PM, Prewitt LM, et al. Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. University of California, San Diego. Chest 1998; 113: 619-624.
-
(1998)
University of California, San Diego. Chest
, vol.113
, pp. 619-624
-
-
Eakin, E.G.1
Resnikoff, P.M.2
Prewitt, L.M.3
-
16
-
-
80051819865
-
Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis
-
du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184: 459-466.
-
(2011)
Am J Respir Crit Care Med
, vol.184
, pp. 459-466
-
-
Du Bois, R.M.1
Weycker, D.2
Albera, C.3
-
17
-
-
79955520497
-
Six-minute-walk test in idiopathic pulmonary fibrosis: Test validation and minimal clinically important difference
-
du Bois RM, Weycker D, Albera C, et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med 2011; 183: 1231-1237.
-
(2011)
Am J Respir Crit Care Med
, vol.183
, pp. 1231-1237
-
-
Du Bois, R.M.1
Weycker, D.2
Albera, C.3
-
18
-
-
76549135612
-
The 6 minute walk in idiopathic pulmonary fibrosis: Longitudinal changes and minimum important difference
-
Swigris JJ, Wamboldt FS, Behr J, et al. The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference. Thorax 2010; 65: 173-177.
-
(2010)
Thorax
, vol.65
, pp. 173-177
-
-
Swigris, J.J.1
Wamboldt, F.S.2
Behr, J.3
-
19
-
-
84930960053
-
Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis
-
Nathan SD, du Bois RM, Albera C, et al. Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis. Respir Med 2015; 109: 914-922.
-
(2015)
Respir Med
, vol.109
, pp. 914-922
-
-
Nathan, S.D.1
Du Bois, R.M.2
Albera, C.3
-
20
-
-
84899830690
-
6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis
-
du Bois RM, Albera C, Bradford WZ, et al. 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J 2014; 43: 1421-1429.
-
(2014)
Eur Respir J
, vol.43
, pp. 1421-1429
-
-
Du Bois, R.M.1
Albera, C.2
Bradford, W.Z.3
-
21
-
-
84865207687
-
The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis
-
Swigris JJ, Han M, Vij R, et al. The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis. Respir Med 2012; 106: 1447-1455.
-
(2012)
Respir Med
, vol.106
, pp. 1447-1455
-
-
Swigris, J.J.1
Han, M.2
Vij, R.3
-
22
-
-
85100415918
-
-
Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Date last accessed: November 17
-
Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org Date last accessed: November 17, 2015.
-
(2015)
Cochrane Handbook for Systematic Reviews of Interventions
-
-
Higgins, J.P.T.1
Green, S.2
-
23
-
-
84906046346
-
IPF clinical trial design and endpoints
-
Nathan SD, Meyer KC. IPF clinical trial design and endpoints. Curr Opin Pulm Med 2014; 20: 463-471.
-
(2014)
Curr Opin Pulm Med
, vol.20
, pp. 463-471
-
-
Nathan, S.D.1
Meyer, K.C.2
-
24
-
-
77951170794
-
Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis
-
Zappala CJ, Latsi PI, Nicholson AG, et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 830-836.
-
(2010)
Eur Respir J
, vol.35
, pp. 830-836
-
-
Zappala, C.J.1
Latsi, P.I.2
Nicholson, A.G.3
-
25
-
-
84975801947
-
Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS
-
Costabel U, Inoue Y, Richeldi L, et al. Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS. Am J Respir Crit Care Med 2016; 193: 178-185.
-
(2016)
Am J Respir Crit Care Med
, vol.193
, pp. 178-185
-
-
Costabel, U.1
Inoue, Y.2
Richeldi, L.3
-
26
-
-
84954305088
-
Pirfenidone for idiopathic pulmonary fibrosis: Analysis of pooled data from the three multinational phase 3 trials
-
Noble PW, Albera C, Bradford WZ, et al. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from the three multinational phase 3 trials. Eur Respir J 2016; 47: 243-253.
-
(2016)
Eur Respir J
, vol.47
, pp. 243-253
-
-
Noble, P.W.1
Albera, C.2
Bradford, W.Z.3
-
27
-
-
84938125365
-
An official ATS/ERS/JRS/ALAT clinical practice guideline: Treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline
-
Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 2015; 192: e3-e19.
-
(2015)
Am J Respir Crit Care Med
, vol.192
, pp. e3-e19
-
-
Raghu, G.1
Rochwerg, B.2
Zhang, Y.3
|